Literature DB >> 8880512

Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients.

X Forns1, M D Maluenda, F X López-Labrador, S Ampurdanès, E Olmedo, J Costa, P Simmonds, J M Sánchez-Tapias, M T Jimenez De Anta, J Rodés.   

Abstract

Hepatitis C virus (HCV) genotypes may be investigated by a variety of laboratory methods that target different parts of the HCV genome and have various degrees of technical difficulty. Since the choice of a particular method is difficult, we compared the performance of (i) a type-specific PCR with type-specific primers from the core region, (ii) molecular hybridization of the PCR-amplified 5' noncoding region to type-specific probes, and (iii) identification of type-specific antibodies against epitopes of nonstructural region 4 by enzyme-linked immunosorbent assay (ELISA). One hundred fifty-one patients with biopsy-proved chronic hepatitis and HCV RNA in serum were investigated. The HCV genotype was identified in 99%, 100%, and 85% of the cases by type-specific PCR, probe hybridization, and ELISA, respectively. The type-specific PCR disclosed infection with type 1a in 3%, type 1b in 74%, and type 3a in 4% of the cases and suggested infection with two or more HCV types, including 2a/2c and 2b, in the remaining 18%. Apparently mixed infections were more prevalent in patients with past intravenous drug use (P < 0.001), but cloning and sequencing of PCR products did not confirm a mixed infection in any of the four cases investigated. Concordant results were obtained by the three procedures with virtually all of the samples in which the type-specific PCR revealed a single HCV genotype. Type-specific hybridization and ELISA usually recognized the genotype producing the strongest DNA band in samples in which type-specific PCR suggested a mixed infection. In conclusion, the three procedures evaluated in this study are reliable for investigation of HCV genotype. Type-specific PCR provides information about HCV subtypes, but a mixed infection detected with this method should be interpreted with caution.

Entities:  

Mesh:

Year:  1996        PMID: 8880512      PMCID: PMC229308          DOI: 10.1128/jcm.34.10.2516-2521.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein.

Authors:  A Machida; H Ohnuma; F Tsuda; E Munekata; T Tanaka; Y Akahane; H Okamoto; S Mishiro
Journal:  Hepatology       Date:  1992-10       Impact factor: 17.425

2.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Genetic organization and diversity of the hepatitis C virus.

Authors:  Q L Choo; K H Richman; J H Han; K Berger; C Lee; C Dong; C Gallegos; D Coit; R Medina-Selby; P J Barr
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

4.  Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus.

Authors:  K Yoshioka; S Kakumu; T Wakita; T Ishikawa; Y Itoh; M Takayanagi; Y Higashi; M Shibata; T Morishima
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

5.  At least five related, but distinct, hepatitis C viral genotypes exist.

Authors:  T A Cha; E Beall; B Irvine; J Kolberg; D Chien; G Kuo; M S Urdea
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

6.  Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.

Authors:  H Okamoto; M Kojima; S Okada; H Yoshizawa; H Iizuka; T Tanaka; E E Muchmore; D A Peterson; Y Ito; S Mishiro
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

7.  Clinical backgrounds of the patients having different types of hepatitis C virus genomes.

Authors:  N Takada; S Takase; N Enomoto; A Takada; T Date
Journal:  J Hepatol       Date:  1992-01       Impact factor: 25.083

8.  Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants.

Authors:  S W Chan; F McOmish; E C Holmes; B Dow; J F Peutherer; E Follett; P L Yap; P Simmonds
Journal:  J Gen Virol       Date:  1992-05       Impact factor: 3.891

9.  Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals.

Authors:  T Tanaka; N Kato; M Nakagawa; Y Ootsuyama; M J Cho; T Nakazawa; M Hijikata; Y Ishimura; K Shimotohno
Journal:  Virus Res       Date:  1992-04       Impact factor: 3.303

10.  Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources.

Authors:  H Okamoto; Y Sugiyama; S Okada; K Kurai; Y Akahane; Y Sugai; T Tanaka; K Sato; F Tsuda; Y Miyakawa
Journal:  J Gen Virol       Date:  1992-03       Impact factor: 3.891

View more
  15 in total

1.  Distribution of HCV genotypes among risk groups in Serbia.

Authors:  G Stamenkovic; S Zerjav; Z M Velickovic; K Krtolica; V L Samardzija; L Jemuovic; D Nozic; B Dimitrijevic
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

Review 2.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

3.  Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes.

Authors:  Linda Cook; KaWing Sullivan; Elizabeth M Krantz; Arthur Bagabag; Keith R Jerome
Journal:  J Clin Microbiol       Date:  2006-09-20       Impact factor: 5.948

4.  Comparison and application of a novel genotyping method, semiautomated primer-specific and mispair extension analysis, and four other genotyping assays for detection of hepatitis C virus mixed-genotype infections.

Authors:  Y W Hu; E Balaskas; M Furione; P H Yen; G Kessler; V Scalia; L Chui; G Sher
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

5.  Genotyping of hepatitis C virus isolates using CLIP sequencing.

Authors:  R S Ross; S O Viazov; C D Holtzer; A Beyou; A Monnet; C Mazure; M Roggendorf
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

6.  Hepatitis G virus infection in chronic liver disease.

Authors:  M Guilera; J C Sáiz; F X López-Labrador; E Olmedo; S Ampurdanés; X Forns; J Bruix; A Parés; J M Sánchez-Tapias; M T Jiménez de Anta; J Rodés
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

7.  Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection.

Authors:  G C Harcourt; M Lucas; A J Godkin; M Kantzanou; R E Phillips; P Klenerman
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

8.  Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain.

Authors:  T Laskus; L F Wang; M Radkowski; H Vargas; M Nowicki; J Wilkinson; J Rakela
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

9.  Mixed genotype infections with hepatitis C virus, Pakistan.

Authors:  Sadia Butt; Muhammad Idrees; Irshad Ur Rehman; Haji Akbar; Muhammad Shahid; Samia Afzal; Saima Younas; Iram Amin
Journal:  Emerg Infect Dis       Date:  2011-08       Impact factor: 6.883

10.  Evaluation of multiplex nested polymerase chain reaction for routine hepatitis C virus genotyping in egyptian patients.

Authors:  Mohamed Abbas Shemis; Dina Mohamed El-Abd; Dalia Ibrahim Ramadan; Mohamed Ibrahim El-Sayed; Bassem Shenoda Guirgis; Mohamed Ali Saber; Hassan Mohamed El-Said Azzazy
Journal:  Hepat Mon       Date:  2012-04-30       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.